Want to see PIII full AI Analyst Report?
PIII Stock Chart & Stats
$9.22
$0.86(8.94%)
At close: 4:00 PM EDT
$9.22
$0.86(8.94%)
Day’s Range― - ―
52-Week Range$1.52 - $16.89
Previous Close$10.48
Volume34.66K
Average Volume (3M)52.49K
Market Cap
$65.78M
Enterprise Value$374.70
Total Cash (Recent Filing)$21.27M
Total Debt (Recent Filing)$130.27M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Nov 18, 2026EPS Estimate
-3.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-32.95
Shares Outstanding3,911,962
10 Day Avg. Volume20,665
30 Day Avg. Volume52,491
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.07
Price to Sales (P/S)0.00782
P/FCF Ratio-0.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$18.00Price Target Upside95.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-12.08
Revenue Forecast (FY)$1.55B
Bulls Say, Bears Say
Bulls Say
Strong Revenue Growth And Higher Per-member FundingRapid revenue expansion and higher funding per attributed member support the economics of P3’s value-based model. These trends can improve operating leverage and provider-partner returns if the company sustains membership quality and contract performance.
Core Operations Reached Positive EBITDAPositive underlying EBITDA indicates the core business is progressing beyond reported settlement benefits. The raised full-year outlook also suggests improving visibility, although execution must continue to convert operational gains into durable profitability.
Improving Medical Cost Management And Clinical ExecutionLower medical-cost trends and scalable care-gap technology strengthen P3’s value proposition to payers and providers. Better utilization and quality outcomes can support recurring performance payments and margins across future contract periods.
Bears Say
Persistent Losses And Substantial Cash BurnThe company continues to consume significant cash despite revenue growth and improving losses. Persistent negative operating cash flow raises financing dependence and limits flexibility to invest in expansion, technology, and provider-market development.
Reported Profitability Relies Heavily On Nonrecurring SettlementsLarge one-time contributions make headline EBITDA a weaker measure of sustainable earnings power. Future results will depend more heavily on medical-cost control, quality execution, and contract economics rather than prior-period favorable developments.
Limited Liquidity And Higher Long-term Financing CostsA modest cash balance combined with capitalized interest preserves near-term cash but increases obligations over time. This can constrain strategic flexibility and heighten refinancing risk if operating cash generation does not become consistently positive.
P3 Health Partners News
PIII FAQ
What was P3 Health Partners’s price range in the past 12 months?
P3 Health Partners lowest stock price was $1.52 and its highest was $16.89 in the past 12 months.
What is P3 Health Partners’s market cap?
P3 Health Partners’s market cap is $65.78M.
When is P3 Health Partners’s upcoming earnings report date?
P3 Health Partners’s upcoming earnings report date is Nov 18, 2026 which is in 76 days.
How were P3 Health Partners’s earnings last quarter?
P3 Health Partners released its earnings results on Aug 10, 2026. The company reported -$0.63 earnings per share for the quarter, beating the consensus estimate of -$1.895 by $1.265.
Is P3 Health Partners overvalued?
According to Wall Street analysts P3 Health Partners’s price is currently Undervalued.
Does P3 Health Partners pay dividends?
P3 Health Partners does not currently pay dividends.
What is P3 Health Partners’s EPS estimate?
P3 Health Partners’s EPS estimate is -3.97.
How many shares outstanding does P3 Health Partners have?
P3 Health Partners has 3,911,962 shares outstanding.
What happened to P3 Health Partners’s price movement after its last earnings report?
P3 Health Partners reported an EPS of -$0.63 in its last earnings report, beating expectations of -$1.895. Following the earnings report the stock price went down -3.585%.
Which hedge fund is a major shareholder of P3 Health Partners?
Currently, no hedge funds are holding shares in PIII
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
P3 Health Partners Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (95.23% Upside)
$18.00 (95.23% Upside)
Blogger Sentiment
Bearish
PIII Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $823.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.55%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
P3 Health Partners
P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. The company operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.
PIII Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear operational progress: revenue growth, improved per-member funding (+15% YoY), positive underlying adjusted EBITDA (≈$9M Q2, ≈$18M H1), a lowered MA medical cost trend (‑1.8% vs. 2025) and upgraded full-year guidance to $80M–$110M. However, a sizable portion of reported profitability in H1 (≈$62M) came from favorable payer settlements and prior-period development, introducing nonrecurring support to headline results. Management emphasizes that the core business is now generating positive EBITDA and is executing on clinical, technology and contractual initiatives to sustain performance, but back-half seasonality, membership concentration and a modest cash balance are risks to monitor. Overall, the positives and momentum outweigh the cautions, though sustainability will depend on continued execution and fewer one-time contributions.View all PIII earnings summariesPIII Stock 12 Month Forecast
Average Price Target
$18.00
▲(95.23% Upside)
Technical Analysis
Ownership Overview
18.65% Insiders
12.17% Mutual Funds
1.68% Other Institutional Investors
66.44% Public Companies and
Individual Investors